Literature DB >> 22414101

Anti-inflammatory agents from plants: progress and potential.

M C Recio1, I Andujar, J L Rios.   

Abstract

The identification of substances that can promote the resolution of inflammation in a way that is homeostatic, modulatory, efficient, and well-tolerated by the body is of fundamental importance. Traditional medicines have long provided front-line pharmacotherapy for many millions of people worldwide. Medicinal extracts are a rich source of therapeutic leads for the pharmaceutical industry. The use of medicinal plant therapies to treat chronic illness, including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), is thus widespread and on the rise.The aim of this review is to present recent progress in clinical anti-inflammatory studies of plant extracts and compound leads such as green tea polyphenols, curcumin, resveratrol, boswellic acid, and cucurbitacins, among others, against chronic inflammatory diseases, mainly RA and IBD. In this context, the present paper also highlights the most promising experimental data on those plant extracts and pure compounds active in animal models of the aforementioned diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22414101     DOI: 10.2174/092986712800229069

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  50 in total

1.  Anti-allergic and anti-inflammatory activity of Phellinus linteus grown on Panax ginseng.

Authors:  Hye-Jin Park
Journal:  Food Sci Biotechnol       Date:  2017-04-30       Impact factor: 2.391

Review 2.  Plants and their active compounds: natural molecules to target angiogenesis.

Authors:  Kai Lu; Madhavi Bhat; Sujit Basu
Journal:  Angiogenesis       Date:  2016-05-06       Impact factor: 9.596

3.  Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes.

Authors:  Jun Wang; Jennifer Blaze; Fatemeh Haghighi; Seunghee Kim-Schulze; Urdvha Raval; Kyle J Trageser; Giulio Maria Pasinetti
Journal:  Mol Immunol       Date:  2020-07-21       Impact factor: 4.407

Review 4.  Research developments in the syntheses, anti-inflammatory activities and structure-activity relationships of pyrimidines.

Authors:  Haroon Ur Rashid; Marco Antonio Utrera Martines; Adriana Pereira Duarte; Juliana Jorge; Shagufta Rasool; Riaz Muhammad; Nasir Ahmad; Muhammad Naveed Umar
Journal:  RSC Adv       Date:  2021-02-03       Impact factor: 3.361

5.  Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway.

Authors:  Jingjing Zhang; Wei Dou; Eryun Zhang; Aning Sun; Lili Ding; Xiaohui Wei; Guixin Chou; Sridhar Mani; Zhengtao Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-14       Impact factor: 4.052

6.  Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-κB pathway in macrophages and splenocytes.

Authors:  Chai Siah Ku; Tho X Pham; Youngki Park; Bohkyung Kim; Min Sun Shin; Insoo Kang; Jiyoung Lee
Journal:  Biochim Biophys Acta       Date:  2013-01-26

Review 7.  The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.

Authors:  Sinyi Kong; Pricilla Yeung; Deyu Fang
Journal:  J Genet Genomics       Date:  2013-04-12       Impact factor: 4.275

Review 8.  Micronutrients: Essential Treatment for Inflammatory Arthritis?

Authors:  Marina Bañuls-Mirete; Alexis Ogdie; Monica Guma
Journal:  Curr Rheumatol Rep       Date:  2020-10-26       Impact factor: 4.592

9.  Curcumin protects against collagen-induced arthritis via suppression of BAFF production.

Authors:  Gang Huang; Zhizhen Xu; Yan Huang; Xiaojun Duan; Wei Gong; Yan Zhang; Jishan Fan; Fengtian He
Journal:  J Clin Immunol       Date:  2012-11-27       Impact factor: 8.317

Review 10.  Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies.

Authors:  Qin Wang; Xianyan Qin; Jiyu Fang; Xun Sun
Journal:  Acta Pharm Sin B       Date:  2021-03-12       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.